K-SEPT 1000

K-Sept 1000 - Powerful Debridement

Hard-to-heal wounds represent a major Issue; medically, economically and pshycologically.
In many cases especially diabetic patients, the end solution is to amputate the wounded limb.

Roughly 50% of Diabetic Foot Ulcers become infected and about one in five of these patients will undergo a lower extremity amputation (LEA). In 2016 130,000 Americans were hospitalized for a LEA.

In Israel, around 75% of LEA’s are among diabetic patients and every year there are at least 1,500 LEA’s. The related economic burden is heavy. With effective treatment, many amputations can be prevented.

K-Sept 1000 provides powerful debridement. The patented K-Sept blue solution acts by softening of necrotic tissue, prevention of microbial growth, debris removal and exudate absorption.

K-Sept 1000 is supported by vast clinical experience. It comes in a box of 25 effervescent tablets and registered for “debridement, irrigation, hygiene and cleaning for wounds & skin”. 

K-Sept 1000, with its powerful debridement capability, facilitates the critical shift from Inflammation to Granulation, thus paving the way to wound healing.

Hard-to-Heal Wounds - A Major Issue

By Scope and Severity, by Economic Burden, by Psychosocial Impact

  • In the USA, more than 30M have diabetes (CDC 2020)
  • 25% of US diabetics develop Diabetic Foot Ulcers (CDC)
  • Diabetic Foot Ulcers cost USA $30 billion yearly (Rogers)
  • Pressure ulcers develop in 29% of long Israeli hospitalizations (MOH)
  • Pressure ulcers are “a heavy economic burden” on Israeli healthcare system (MOH)
  • Anxiety and depression are associated with delayed healing in leg ulceration (Cole-King)
  • Amputations are (often) Preventable

  • 50% of Diabetic Foot Ulcers become infected (Lavery)
  • 1 in 5 will undergo a lower extremity amputation (Lavery)
  • 75% of Israeli LEA’s are among diabetics (Research Center, the Knesset)
  • 3 of 1000 Israeli diabetics undergoe an amputation (Res. Center, the Knesset)
  • At least 1,500 LEA’s in Israel, every year (!)
  • Preventable event in 85% of diabetic LEA’s (Pecoraro)
  • K-Sept 1000 - Physical & Use Features

  • Effervescent tablets based on a patented formulation
  • Tablet in 1 L. water provides 1000ppm LAC (Latent Available Chlorine)
  • Blue solution for easy identification
  • Good for use for 48 hours
  • Lightly shake before use
  • pH of solution is 5 to 6, neutral to skin & tissue
  • 25 tablets in a transparent bottle
  • Frequent wetting – essential for facilitating the debridement
  • K-Sept 1000 - Powerful & Proven Debridement

    Effective – Safe – Proven – Easy to Use

    • Backed by vast clinical experience (since 1982)
    • Supported by leading Plastic Surgeons and DFU Specialists
    • Effective for various types of wounds (infected, necrotic // diabetic, neuropathic // burns, amputations // open fractures, crash injuries)
    • Acts by softening necrotic tissue, prevention of microbial growth, debris removal, exudate absorption
    • Facilitates the critical shift from Inflammation to Granulation

    INDICATIONS: debridement, irrigation, hygiene and cleaning solution for wounds & skin (AMAR license 1700405)

    Continuous renewal of solution on the wound (via frequent dressing wetting) is essential for facilitating wound healing.

    For Treatment Examples with K-Sept 1000 (Before & After Images)   –


    • CDC National Diabetes Statistics Report, 2020.
    • National Diabetes Fact Sheet: General information and national estimates on diabetes in the United States, US Department of Health and Human Services, 2005.
    • Lavery LA, et al. The right to bear legs – how preventing amputations can save billions to the US healthcare system. J Am Podiatr Med Assoc 2008.
    • Pressure Ulcers in Israeli hospitals, Quality Assurance Division, MOH, 2018
    • Cole-King A, Harding KG. Psychological factors and delayed healing in chronic wounds. Psychosom Med 2001.
    • Lavery LA, et al. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003.
    • Data on Diabetes in Israel, Center of Information and Research, the Knesset, 2010.
    • Pecoraro RE, et al. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990.

    K-Sept 1000 – Filling Bottles

    For preparing the K-Sept 1000 solution, you can use K-Sept designated filling bottles. These 1 Liter bottles come with ready labels and 2 forms of closure, cap and sprayer. This enables pouring or spraying, as preferred by the practitioner. The filling bottles have been lab tested and found suitable for their purpose. They ensure consistency of practice in the clinical setting and – via the ready label – assist in avoiding identification mistakes. There is also a designated space for adding the date of preparing the solution (thus ensuring use within the recommended time frame of 48H after preparation).

    K-Sept 1000 - Powerful Debridement​

    Skip to content